### External request:

Submission from Genentech Inc., to recommend entrectinib and appropriate NTRK gene fusion testing for the treatment of NTRK gene fusion-positive ovarian cancer.

Based on a review of data, the panel consensus supported the inclusion of the following targeted recurrence therapy options under “useful in certain circumstances” for platinum-sensitive and platinum-resistant ovarian cancer: Entrectinib or larotrectinib (for NTRK gene fusion-positive tumors).

The panel supported an addition on OV-6/7, in footnote w:

- Validated molecular testing should be performed in a CLIA-approved facility using the most recent available tumor tissue. Testing recommended to include at least: BRCA1/2, and microsatellite instability or DNA mismatch repair if not previously done. Evaluation of homologous recombination deficiency can be considered. Additional somatic tumor testing can be considered at the physician’s discretion to identify genetic alterations for which FDA-approved tumor-specific or tumor-agnostic targeted therapy options exist.

See Submission for references.